Jul 30, 2025 7:04am EDT Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Jul 28, 2025 7:00am EDT Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Jun 16, 2025 9:00am EDT Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
May 05, 2025 8:00am EDT Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Apr 17, 2025 8:55am EDT Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Apr 14, 2025 2:28pm EDT Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Apr 14, 2025 8:30am EDT Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Mar 24, 2025 9:00am EDT Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
